US: 1.646.568.9797 (24x5)
UK: 44.330.808.0580 (24x5)
Worldwide: 91.703.051.960 (24x7)
Abstract, Snapshot, Market Analysis & Market Definition: Global Crohn’s Disease Therapeutics Market The global Crohn’s disease therapeutics market size was estimated at USD 3.8 billion in 2016 and is expected to register a CAGR of 2.4% during the forecast period. Growing prevalence of the disease, along with increase in number of pipeline drugs, is expected to be a key factor driving the market. Prevalence of Crohn’s disease has increased in developing countries owing to industrialization, environmental factors such as differences in exposure to sunlight, changes in diet, smoking, and genetic characteristics. According to the Centers for Disease Control and Prevention (CDC), over 1 million Americans suffer from inflammatory bowel disease every year. Constant efforts in the development of biosimilars is steering industry growth. Low cost of biosimilars is one of its major benefits, which has resulted in cumulative savings within the healthcare system in U.S. and Europe. Reduced cost can result in increased access to biologic therapies, thus improving patient care. Rising development of novel biological agents and anti-cytokine agents with a different mechanism of action and use of stem cells in treating the disease is anticipated to drive the industry in future. For instance, Infliximab and Adalimumab are some of the TNF-agents that have proved to be efficacious in treating the condition. In addition, increase in number of pipeline drugs is anticipated to accentuate growth. Currently, there are around 40 drugs in the pipeline and commercialization of five drugs is expected in 2019. For instance, Celgene Corporation’s mongersen (GED-0301) is currently in phase III trial for Crohn’s disease and is expected to be launched in 2019. As of 2016, 27 biosimilars were in the pipeline, with 11 of them in phase III trials. Market Segmentation, Outlook & Viewpoint: Global Crohn’s Disease Therapeutics Market Therapy Type Market Segmentation & Outlook (Revenue, USD Million, 2014 - 2025) Non-Surgical Anti-Inflammatory Immune system suppressors Antibiotics Others Surgical Key Players, Recent Developments & Regional Insights: Global Crohn’s Disease Therapeutics Market Based on therapy type, the market is broadly categorized into surgical and non-surgical, with the latter comprising anti-inflammatory, immune system suppressors, antibiotics, and others. The anti-inflammatory segment dominated the overall Crohn’s disease therapeutics market in terms of revenue in 2016. Anti-inflammatories are first line therapy drugs and are more targeted and effective. The immune system suppressors segment is slated to clock a CAGR of 3.2% during the forecast period. Immune system suppressors have shown promising safety and efficacy. Reduced rate of mortality, hospitalization, and surgery, coupled with improved patient quality of life, is expected to drive the segment. Companies such as Genentech Inc. and Celgene Corporation are currently focusing on developing immune system suppressors for the treatment of this condition. For instance, etrolizumab of Genentech Inc., an immune system suppressor, is under clinical investigation. This drug has shown promising safety and efficacy in phase II clinical studies. Approval of these products may support the growth of this segment in future. Regional Insights North America dominated the global market in terms of revenue in 2016. Established R&D infrastructure, development of novel therapeutics, and rising prevalence of the disease are key factors contributing to its growth. According to the Crohn’s & Colitis Foundation, 1.6 million Americans suffer from the condition. High prevalence of the condition, along with strong healthcare infrastructure, has triggered the introduction of initiatives for novel treatment methods and making them accessible to patients. Europe was the second-largest revenue generating region in 2016. Highly established healthcare infrastructure, coupled with rise in disease prevalence and increase in R&D initiatives, is expected to drive the regional market. The Asia Pacific market is poised to exhibit a CAGR of 4.2% over the forecast period. Japan and China are considered to be the most promising markets in the region. Change in dietary habits augments market growth. Crohn’s Disease Therapeutics Market Share Insights The global market is marked by extensive strategic collaboration as a result of its consolidated nature. Some of the major players are Johnson & Johnson Services Inc.; Pfizer Inc.; Allergan; AbbVie Inc.; Takeda Pharmaceutical Company Limited; Celgene Corporation; Perrigo Company PLC; Ferring B.V.; Salix Pharmaceuticals; Gilead Sciences Inc.; Genentech Inc.; and UCB India Private Limited. Collaborations with research institutes and acquisitions of small players are key strategies undertaken by players to attain a stable position in the market. Focus is also on development of novel products for treatment. For instance, in 2016, Johnson & Johnson announced the approval of Stelara by the FDA for the treatment of Crohn’s disease. Key Insights Covered: Global Crohn’s Disease Therapeutics Market 1. North America, Europe, Asia Pacific, Middle East & Africa, Latin America market size (sales, revenue and growth rate) of Crohn’s Disease Therapeutics industry. 2. Global major manufacturers' operating situation (sales, revenue, growth rate and gross margin) of Crohn’s Disease Therapeutics industry. 3. Global major countries (United States, Canada, Germany, France, UK, Italy, Russia, Spain, China, Japan, Korea, India, Australia, New Zealand, Southeast Asia, Middle East, Africa, Mexico, Brazil, C. America, Chile, Peru, Colombia) market size (sales, revenue and growth rate) of Crohn’s Disease Therapeutics industry. 4. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Crohn’s Disease Therapeutics industry. 5. Global market size (sales, revenue) forecast by regions and countries from 2019 to 2024 of Crohn’s Disease Therapeutics industry. Research Methodology: Global Crohn’s Disease Therapeutics Market
- Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request a Sample Report.
- Demand Side Primary Contributors: OEMs, Industrial Professionals, Researches, Suppliers and Distributors, Group Purchasing Organizations, Associations, Insurers, Universities, Technological Writers, Scientists, Promoters, Investors among others.
- Supply Side Primary Contributors: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, Regulatory Affairs Managers among other
Table of Contents Chapter 1 Methodology & Scope 1.1. Research Methodology 1.2. Research Scope & Assumptions 1.3. List of Data SourcesChapter 2. Executive Summary 2.1. Market SnapshotChapter 3. Crohn’s Disease Therapeutics Industry Outlook 3.1. Market segmentation 3.2. Market size and growth prospects, 2014 - 2025 3.3. Value chain analysis 3.4. Regulatory Framework 3.5. Market dynamics 3.5.1. Market driver analysis 3.5.2. Market restraint analysis 3.6. Key opportunities prioritized 3.7. Industry analysis - Porter's 3.8. PESTEL analysis, 2016Chapter 4. Crohn’s Disease Ther | read more...